Erythropoiesis‐stimulating agents and incident malignancy in chronic kidney and end‐stage renal disease: A population‐based study

• Main Authors: Yu‐Shan Huang (Author), Ming‐Feng Li (Author), Mei‐Chen Lin (Author), Shih‐Hsiang Ou (Author), Jen‐Hung Wang (Author), Chien‐Wei Huang (Author), Kang‐Ju Chou (Author), Hua‐Chang Fang (Author), Po‐Tsang Lee (Author), Chih‐Yang Hsu (Author), Jin‐Shuen Chen (Author), Hsin‐Yu Chen (Author)
• Format: Book
• Published: Wiley, 2022-09-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract Research investigating incident malignancy risk in erythropoiesis‐stimulating agent (ESA) users with chronic kidney disease (CKD) is lacking. We aimed to compare the incident cancer risk between ESA and non‐ESA users with CKD or end‐stage renal disease (ESRD). In this retrospective cohort s...